Protalix BioTherapeutics (PLX) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.20% |
| Dec 31, 2025 | -6.31% |
| Sep 30, 2025 | -6.84% |
| Jun 30, 2025 | 9.44% |
| Mar 31, 2025 | 4.61% |
| Dec 31, 2024 | 22.61% |
| Sep 30, 2024 | 48.45% |
| Jun 30, 2024 | 48.54% |
| Mar 31, 2024 | 27.60% |
| Dec 31, 2023 | 26.74% |
| Sep 30, 2023 | 121.59% |
| Jun 30, 2023 | 77.69% |
| Mar 31, 2023 | 54.51% |
| Dec 31, 2022 | 63.59% |
| Sep 30, 2022 | -13.65% |
| Jun 30, 2022 | 12.30% |
| Mar 31, 2022 | 47.93% |
| Dec 31, 2021 | 13.39% |
| Sep 30, 2021 | 16.11% |
| Jun 30, 2021 | 10.56% |
| Mar 31, 2021 | 16.82% |
| Dec 31, 2020 | 21.50% |
| Sep 30, 2020 | 13.82% |
| Jun 30, 2020 | -13.26% |
| Mar 31, 2020 | 0.57% |
| Mar 31, 2019 | -15.42% |
| Dec 31, 2018 | -8.05% |
| Sep 30, 2018 | -15.04% |
| Jun 30, 2018 | -58.46% |
| Mar 31, 2018 | -46.13% |
| Dec 31, 2017 | -51.34% |
| Sep 30, 2017 | -54.63% |
| Jun 30, 2017 | -52.13% |
| Mar 31, 2017 | -1.77% |
| Dec 31, 2016 | 7.41% |
| Sep 30, 2016 | 12.12% |
| Jun 30, 2016 | 12.32% |
| Mar 31, 2016 | 9.15% |
| Dec 31, 2015 | -0.62% |
| Sep 30, 2015 | 25.72% |
| Jun 30, 2015 | 29.69% |